Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Biosimilars reduce financial burden for cancer patients and insurers

Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care.

27 Aug 2026

Real-world Chinese study confirms benefits of niraparib maintenance therapy for ovarian cancer

Ovarian cancer remains one of the most lethal gynecologic malignancies worldwide, with a high risk of recurrence even after successful initial treatment.

26 Aug 2026

New microfluidic chip predicts personalized glioblastoma treatment responses

Even for the same brain tumor treated with the same anticancer drug, the effect can differ from patient to patient.

17 Aug 2026

Combination therapy improves progression-free survival in dMMR/MSI-H metastatic colorectal cancer

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

29 Jul 2026

Phase 3 clinical trial enrolls first platinum-resistant ovarian cancer patient

The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer.

27 Jul 2026

Integrating gene signatures and multi omics improves liver cancer treatment

Hepatocellular carcinoma (HCC) remains highly fatal due to late diagnosis and scarce early biomarkers.

14 Jul 2026

Altering gut microbes could improve immunotherapy responses in liver cancer

Immune checkpoint blockade (ICB) has reshaped the treatment landscape for advanced hepatocellular carcinoma (HCC), offering new hope where few options existed.

30 Jun 2026

Targeting IGF2BP2 improves anti-angiogenic therapy effectiveness in colorectal cancer

A recent study published in Engineering has shed light on a novel therapeutic target for improving anti-angiogenic treatment in colorectal cancer (CRC).

10 Mar 2026

Armored CAR T cells overcome tumor defenses in solid cancers

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor microenvironment, a protective shield that tumors use to weaken immune cells, block their attack and fuel tumor growth.

4 Mar 2026

Prognostic nutritional index proposed as prognostic marker in hepatocellular carcinoma

The prognostic nutritional index (PNI), calculated from serum albumin and lymphocyte count, reflects a patient's immune-nutritional status and has been proposed as a prognostic marker in hepatocellular carcinoma (HCC).

27 Jan 2026

Remodeling the tumor microenvironment to unlock CAR-T cell potential

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME).

22 Dec 2025

Dinutuximab beta plus chemotherapy shrinks neuroblastoma tumors in children

Children with a rare form of cancer called neuroblastoma which hasn't responded to initial treatment or that has relapsed may benefit from adding antibody treatment to usual chemotherapy, according to new results from a clinical trial.

12 Dec 2025

Toward precision diagnosis and treatment of radiation-induced brain injury

Radiation-induced brain injury (RIBI) is a serious and often delayed complication of cranial radiotherapy, which remains a cornerstone in the treatment of brain tumors such as gliomas, metastases, and lymphomas.

18 Nov 2025

Genetic and cellular mechanisms underlying steatotic liver disease

Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology.

10 Nov 2025

BioDlink Commends Junshi Biosciences as its Bispecific ADC Candidate JS212 Receives IND Approval

BioDlink, a leading global CDMO, extends its congratulations to Junshi Biosciences, on receiving Investigational New Drug (IND) approval

From BioDlink 12 Sep 2025

BioDlink fast-tracks global growth with bevacizumab launch in Colombia and Pakistan

BioDlink announced that its self-developed bevacizumab injection biosimilar has received marketing approval from Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA) and Pakistan’s Drug Regulatory Authority of Pakistan (DRAP).

From BioDlink 8 Sep 2025

Affordable HIV drug shows promise in improving vision for diabetic eye disease

An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more effectively and a much lower cost than many existing treatments, an initial clinical trial suggests.

27 May 2025

Exploring the dual role of LKB1 in tumor suppression and promotion

Mutations in serine-threonine kinase 11 (STK11) and liver kinase B1 (LKB1) are associated with disease progression in Peutz-Jeghers syndrome (PJS), which can progress to cancer.

22 Feb 2025

Triple therapy shows strong response in BRAF V600E mutant metastatic colorectal cancer

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the Phase III BREAKWATER trial led by researchers at The University of Texas MD Anderson Cancer Center.

26 Jan 2025

Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial cell cycle progression.

8 Nov 2024